BOULDER, Colo., Oct. 29, 2014 /PRNewswire/ -- Array BioPharma Inc. ARRY will report financial results for the first quarter of fiscal 2015 and hold a conference call to discuss those results on Tuesday, November 4, 2014. Ron Squarer, Chief Executive Officer and Michael Carruthers, Chief Financial Officer will lead the call.
|
Date: |
Tuesday, November 4, 2014 |
|
Time: |
9:00 a.m. Eastern Time |
|
Toll-Free: |
(800) 708-4540 |
|
Toll: |
(847) 619-6397 |
|
Pass Code: |
38177000 |
|
Webcast, including Replay and Conference Call Slides: | |
|
http://www.media-server.com/m/acs/835a9ca60ab7df8747dc3aa3ad1d878b | |
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Seven Phase 3 studies are in progress, or are planned to begin this year. These programs include the wholly-owned hematology drug, filanesib (ARRY-520) for multiple myeloma and two partnered cancer drugs, selumetinib (AstraZeneca) and binimetinib (MEK162 / Novartis). For more information on Array, please go to www.arraybiopharma.com.
|
CONTACT: |
Tricia Haugeto |
|
Array BioPharma Inc. | |
|
(303) 386-1193 | |
SOURCE Array BioPharma
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
